Disponible en / Available in: Español
On November 8, the fight against Cystic Fibrosis enters a new phase. Kaftrio is already a reality.
Price agreement for Kaftrio
The Ministry of Health and the laboratory Vertex Pharmaceuticals have reached a price agreement for the commercialization of the drug Kaftrio, after more than a year of delay with other countries in our environment.
F508del and any other mutation
As of December 1, 2021, people with Cystic Fibrosis over 12 years of age with at least one copy of the F508del mutation in the CFTR gene, regardless of their other mutation, will be able to receive this drug.
Kaftrio for 70% of people with CF in Spain
70% of the population with Cystic Fibrosis in Spain has at least one F508del mutation, so that the pulmonology team, mainly, will be able to indicate it for those people they deem appropriate.
A before and after
Access to Kaftrio will mean a before and after for a very significant number of people with CF, who will have the opportunity to live their lives without the constant deterioration of their health caused by this disease and will mark a change in the survival of the group.
A treatment with results never seen before
Patients who take it have seen their quality of life change. Within a few treatments, the benefits are already noticeable. Lung function, number of exacerbations, number of exacerbations, nutritional status, symptoms such as cough and expectoration are substantially improved. substantially improved. Patients with advanced severe disease may improve sufficiently to come off the patients with advanced severe disease can improve enough to be removed from transplant lists, making it a treatment with results never seen before.
More treatments to come
The organizations dedicated to the fight against Cystic Fibrosis will not stop until we get effective treatments for the whole group of people with this disease. We still have 30% of the population with Cystic Fibrosis in this situation, so when a laboratory discovers an effective medicine, we will exert pressure so that it becomes available as soon as possible.
What is Cystic Fibrosis?
Cystic Fibrosis is a genetic, serious and degenerative disease that to date has no cure.
It mainly affects the respiratory, digestive, reproductive and sweat glands.
Currently, more than 2000 mutations are known in the gene that is defective in people with Cystic Fibrosis, although only about 150 mutations are described as causing the disease.
Statistics show that 1 in 5,000 people in Spain has Cystic Fibrosis (1 in 6,400 in the Balearic Islands) and 1 in 35 people is a carrier of a gene that causes the disease (1 in 40 in the Balearic Islands).
In the Balearic Islands there are 76 known diagnosed cases, but statistics speak of between 85 and 90 possible cases.
The awareness project of the Respiralia Foundation aims to raise awareness of this disease in order to discover those cases of people who have Cystic Fibrosis but have not yet been diagnosed.